<DOC>
	<DOCNO>NCT00867100</DOCNO>
	<brief_summary>This Phase 1 study evaluate safety , tolerability , PK PD AMG 827 administer single SC IV dose healthy subject ( Part A ) subject moderate severe psoriasis ( Part B ) .</brief_summary>
	<brief_title>Single-Dose Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics AMG 827 Healthy Subjects Subjects With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Part A : Able provide write informed consent Healthy male female 18 45 year age , inclusive time screen Additional inclusion criterion apply Part B : 18 55 year old inclusive Screening Active clinically stable , plaque psoriasis Psoriasis involve ≥ 10 % body surface area A minimum PASI score ≥ 10 obtained screen period Additional inclusion criterion apply Part A : History evidence clinically significant disorder ( include limit cardiopulmonary , oncologic , renal , metabolic , hematologic psychiatric ) , condition disease , opinion Investigator Amgen physician would pose risk subject safety interfere study evaluation , procedures completion Underlying condition predisposes subject infection ( eg , uncontrolled diabetes HbA1c &gt; 7 % , history splenectomy ) Additional exclusion criterion apply Part B : Active guttate , erythrodermic , pustular psoriasis time screen visit Evidence skin condition psoriasis ( eg , eczema ) time screen visit screen visit study drug initiation would interfere evaluation effect investigational product psoriasis Any condition , judgment investigator , might cause study detrimental subject Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>